Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report

Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report

Both sotorasib and adagrasib are approved for use in metastatic KRASG12C-mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered adverse effect of both agents, and little data exists about the safety of sequential use of these agents when hepa...

Full description

Bibliographic Details
Main Authors: Natalie Stratton, BS, Jonathan Thompson, MD, MS
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JTO Clinical and Research Reports
Subjects:
Adagrasib
Sotorasib
Hyperpigmentation
Hepatotoxicity
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000316

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324000316

Similar Items